April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Rates of Vision Loss in Patients with Geographic Atrophy in AREDS and AREDS 2
Author Affiliations & Notes
  • David Valent
    National Eye Institute/National Institutes of Health, Bethesda, MD
  • Emily Y Chew
    National Eye Institute/National Institutes of Health, Bethesda, MD
  • Elvira Agron
    National Eye Institute/National Institutes of Health, Bethesda, MD
  • Frederick L Ferris
    National Eye Institute/National Institutes of Health, Bethesda, MD
  • Philip J Rosenfeld
    Bascom Palmer Eye Institute, Miami, FL
  • Traci E Clemons
    EMMES Corporation, Rockville, MD
  • Wai T Wong
    National Eye Institute/National Institutes of Health, Bethesda, MD
  • Age Related Eye Disease Study Research Group
    EMMES Corporation, Rockville, MD
  • Footnotes
    Commercial Relationships David Valent, None; Emily Chew, None; Elvira Agron, None; Frederick Ferris, None; Philip Rosenfeld, None; Traci Clemons, None; Wai Wong, None; Age Related Eye Disease Study Research Group, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5894. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David Valent, Emily Y Chew, Elvira Agron, Frederick L Ferris, Philip J Rosenfeld, Traci E Clemons, Wai T Wong, Age Related Eye Disease Study Research Group; Rates of Vision Loss in Patients with Geographic Atrophy in AREDS and AREDS 2. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5894.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate the rates of vision loss compared with baseline in participants with geographic atrophy (GA) at baseline and those that developed GA in two major clinical trials.

 
Methods
 

The Age Related Eye Disease Study (AREDS) was a multi-center, double masked randomized clinical trial that enrolled 4757 participants with varying degrees of macular degeneration. The AREDS 2 was a multi-center, double masked phase 3 study which enrolled 4203 participants who were at risk for progression to advanced age related macular degeneration. In both studies, best-corrected visual acuity was obtained at baseline and at yearly intervals using the standard protocol from the Early Treatment of Diabetic Retinopathy Study (ETDRS).

 
Results
 

In AREDS, 259 eyes of 217 participants were identified as having GA at baseline. Of these, 79 had central GA. By the 5 year follow-up, 1267 eyes of 908 participants developed GA, 259 eyes were defined as having central GA. For those with GA at baseline, 48.7% of participants lost more than 10 letters and 36.8% lost more than 15 letters at 5 years compared with baseline. For those that developed GA during follow up, 47.1% of eyes lost more than 10 letters of vision, while 36.8% lost more than 15 letters at 5 years. Participants that developed GA during the study that had better initial visual acuity (20/80 or better), on average lost more letters than those with worse visual acuity when diagnosed with GA at 5 years (20 letters vs. 5.7 letters). In AREDS 2, 524 eyes of 418 participants were identified as having GA at baseline, of which 170 eyes had central GA. By 5 years of follow-up, an additional 868 eyes of 791 participants developed GA, 291 of which had central GA. For those with GA at baseline, 44.2% of participants lost more than 10 letters, and 33.5% lost more than 15 letters at 5 years follow up. For those that developed GA during follow up, 50.0% of participants lost more than 10 letters, and 35.0% lost more than 15 letters at 5 years.

 
Conclusions
 

Participants in the AREDS and AREDS2 study with geographic atrophy trended toward progressive visual loss. As expected, those participants with better initial visual acuity tended to lose more letters than those with worse initial visual acuity. This data may guide other investigators in planning for future studies of GA associated with AMD.

  
Keywords: 412 age-related macular degeneration • 754 visual acuity  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×